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Abstract 
Although  behavioral  addictions  share  many  clinical  features  with  drug  
addictions,  they  show  strikingly  large  variation  in  their  behavioral  
phenotypes  (such  as  in  uncontrollable  gambling  or  eating).  
Neurotransmitter  function  in  behavioral  addictions  is  poorly  understood  
but  has  important  implications  in  understanding  its  relationship  with  
substance  use  disorders  and  underlying  mechanisms  of  therapeutic  
efficacy.  Here,  we  compare  opioid  and  dopamine  function  between  two  
behavioral  addiction  phenotypes:  pathological  gambling  (PG)  and  binge  
eating  disorder  (BED).  Thirty-nine  participants  (15  PG,  7  BED  and  17  
controls)  were  scanned  with  [11C]carfentanil  and  [18F]fluorodopa  positron  
emission  tomography  using  a  high-resolution  scanner.  Binding  potentials  
relative  to  non-displaceable  binding  (BPND)  for  [11C]carfentanil  and  influx  
rate  constant  (Ki)  values  for  [18F]fluorodopa  were  analyzed  with  region-
of-interest  and  whole-brain  voxel-by-voxel  analyses.  BED  subjects  
showed  widespread  reductions  in  [11C]carfentanil  BPND  in  multiple  
subcortical  and  cortical  brain  regions  and  in  striatal  [18F]fluorodopa  Ki  
compared  with  controls.  In  PG  patients,  [11C]carfentanil  BPND  was  
reduced  in  the  anterior  cingulate  with  no  differences  in  [18F]fluorodopa  
Ki  compared  with  controls.  In  the  nucleus  accumbens,  a  key  region  
involved  in  reward  processing,  [11C]Carfentanil  BPND  was  30-34%  lower  
and  [18F]fluorodopa  Ki  was  20%  lower  in  BED  compared  with  PG  and  
controls  (p<0.002).  BED  and  PG  are  thus  dissociable  as  a  function  of  
dopaminergic  and  opioidergic  neurotransmission.  Compared  with  PG,  
BED  patients  show  widespread  losses  of  mu-opioid  receptor  availability  
together  with  presynaptic  dopaminergic  defects.  These  findings  highlight  
the  heterogeneity  underlying  the  subtypes  of  addiction  and  indicate  
differential  mechanisms  in  the  expression  of  pathological  behaviors  and  
responses  to  treatment.  
 
  
	 3	
Introduction 
Behavioral  addictions  refer  to  a  group  of  heterogeneous  conditions  
characterized  by  the  compulsive  pursuit  of  rewards  through  repetitive  
behavioral  patterns.(Robbins and Clark, 2015)  What  constitutes  a  
behavioral  addiction  and  how  they  fundamentally  compare  with  
substance  use  disorders  remain  to  be  fully  defined.  Further,  why  
specific  disorders  are  treatable  with  a  specific  drug  or  expressed  in  
certain  behaviors  remains  elusive.  Currently,  only  gambling  disorder  is  
classified  as  a  behavioral  addiction  in  the  Diagnostic  and  Statistical  
Manual  of  Mental  Disorders,  Version  5  (DSM-5)  with  internet  gaming  
disorder  classified  in  Section  III  as  a  disorder  requiring  more  study.  A  
number  of  other  phenotypically  distinct  behaviors  have  overlapping  
characteristics  including  binge  eating  disorder  (BED),  compulsive  sexual  
behaviors,  and  compulsive  shopping.(Yau and Potenza, 2015)  Pathological  
gambling  (PG)  has  been  viewed  as  a  prototype  of  a  behavioral  
addiction,  with  a  prevalence  of  1-3%.  BED  is  the  most  frequent  of  
eating  disorders(Kessler et al, 2013)  and  is  characterized  by  the  rapid  
intake  of  large  amounts  of  food  in  discrete  periods  of  time  and  the  
lack  of  control  over  eating  behaviors.  The  phenomenology  of  PG  and  
BED  share  many  features  with  substance  addictions(Grant et al, 2010b)  
and  mood  disorders.  Earlier  studies  have  shown  that  depression  
symptoms  are  common  in  both  BED  and  PG  (with  possible  shared  
genetic  factors),  and  antidepressants  have  decreased  binge-eating  
frequency(Brownley et al, 2016; Potenza et al, 2005).  Further,  it  has  been  
suggested  that  a  modification  of  developmental  model  for  major  
depression  could  provide  a  foundation  for  the  development  of  a  
comprehensive  model  on  pathological  gambling(Blanco et al, 2015). 
Understanding  the  underlying  neurobiological  substrates  can  help  in  a  
neurobiologically  driven  conceptualization  of  these  disorders  and  is  
critical  for  future  efforts  in  drug  development.   
 
Substance  use  disorders  are  commonly  associated  with  reduced  striatal  
post-synaptic  D2  receptor  availability  and  blunted  dopamine  responses  
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to  pharmacological  challenge,  such  as  (met)amphetamine.(Volkow et al, 
2014)  In  contrast,  converging  studies  in  PG  have  not  shown  differences  
in  post-synaptic  striatal  dopamine  D2  receptor  availability  compared  with  
healthy  controls.(Boileau et al, 2013; Clark et al, 2012; Joutsa et al, 2012)  
Furthermore,  dopaminergic  responses  to  gambling  or  amphetamine  
challenge  appear  to  be  enhanced  in  PG,  in  contrast  to  substance  use  
disorders.(Boileau et al, 2014; Joutsa et al, 2012)  Similarly,  BED  patients  
have  shown  no  alterations  in  baseline  D2  receptor  availability  with  
increased  striatal  dopamine  responses  to  food  stimuli.(Wang et al, 2011)  
Studies  of  presynaptic  dopamine  function  in  substance  use  disorders  
have  shown  mixed  results.(Bloomfield et al, 2014; Kienast et al, 2013; Wu et 
al, 1997)  Presynaptic  dopamine  function  in  PG  or  BED  have  not  yet  
been  reported.  With  respect  to  mu-opioid  receptor  availability,  PG  
patients  have  not  shown  baseline  differences  but  have  shown  
decreased  opioid  release  to  amphetamine  challenge.(Mick et al, 2015)  No  
studies  of  mu-opioid  receptor  availability  in  BED  have  been  reported.  
Studies  of  in  vivo  neurotransmitter  function  in  PG  and  BED  are  in  their  
infancy.   
 
Understanding  neurotransmitter  function  in  behavioral  addictions  is  
critical  for  the  conceptualization  of  these  behaviors  and  to  understand  
the  mechanisms  underlying  therapeutic  efficacy.  Lisdexamfetamine,  a  
prodrug  of  dextroamphetamine,  is  the  first  and  only  drug  approved  by  
the  Food  and  Drug  Administration  for  the  treatment  of  BED.(McElroy et 
al, 2015)  This  drug  increases  synaptic  dopamine  by  blocking  dopamine  
reuptake  transporters.  Hence,  understanding  presynaptic  dopamine  
function  in  BED  is  highly  relevant.  Rodent  studies  suggest  that  the  
opioid  system  is  implicated  in  hedonic  processing,  incentive  motivation  
and  consummatory  aspects  relevant  particularly  to  binge  eating  (for  
review  see  (Giuliano and Cottone, 2015))  and  other  behavioral  and  
substance  use  disorders.  Opioid  antagonists  have  demonstrated  efficacy  
in  alcohol  use  disorders.(Rosner et al, 2010)  Naltrexone,  a  mu-opioid  
antagonist,  has  also  shown  efficacy  in  some  but  not  all  randomized  
controlled  trials  for  PG.(Grant et al, 2008; Kim et al, 2001; Kovanen et al, 
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2016; Toneatto et al, 2009)  The  efficacy  of  nalmefene  in  PG  is  also  
mixed.(Grant et al, 2010a; Grant et al, 2006)  Two  novel  opioid  antagonists  
selective  for  the  mu-opioid  receptor,  ALKS  33(McElroy et al, 2013)  and  
GSK1521498(Ziauddeen et al, 2013),  have  not  shown  efficacy  in  binge  
eating  behaviors  or  weight,  although  the  latter  demonstrated  effects  on  
hedonic  and  motivational  responses.(Cambridge et al, 2013; Ziauddeen et 
al, 2013)  This  mixed  picture  highlights  the  necessity  of  understanding  
the  underlying  neurotransmitter  profile  to  help  guide  therapeutic  drug  
efficacy. 
 
Here,  we  investigated  mu-opioid  receptor  and  dopamine  
neurotransmission  using  high-resolution  [11C]carfentanil  and  
[18F]fluorodopa  brain  PET  to  directly  compare  two  phenotypically  
different  behavioral  addictions,  PG  and  BED.  We  hypothesized  that  
similar  to  substance  use  disorders,  both  PG  and  BED  would  show  
decreased  presynaptic  dopamine  function  and  increased  mu-opioid  
receptor  binding.
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Material  and  methods 
Subjects 
Sixty-seven  subjects  were  screened  for  the  study  using  clinical  
interviews,  basic  blood  laboratory  tests  and  urine  drug  screens.  Thirteen  
subjects  were  excluded  due  to  scheduling  problems,  four  due  to  unmet  
diagnostic  criteria  for  PG  or  BED,  three  due  to  alcohol  abuse,  two  due  
to  DSM  IV  axis  I  psychiatric  disorder,  and  six  due  to  other  reasons.  
Thirty-nine  subjects  were  included  (17  healthy  controls  (HC),  15  PG  
and  7  BED)  (Table  1).  Fulfilling  the  DSM-IV  diagnostic  criteria  of  BED  
or  PG  was  considered  as  inclusion  criteria  for  the  corresponding  groups  
(Table  2),  and  the  diagnoses  were  confirmed  with  a  structured  clinical  
interview.  None  of  the  subjects  were  using  medications  known  to  have  
effects  on  opioid  or  dopamine  system.  One  PG  patient  was  using  an  
SSRI  medication  citalopram  for  mild  anxiety  symptoms.  The  study  
protocol  was  approved  by  the  local  ethics  committee,  and  written  
informed  consent  was  obtained  from  each  participant.  The  study  was  
conducted  according  to  the  principles  of  the  Declaration  of  Helsinki.   
 
The  subjects  were  instructed  to  refrain  from  cigarette  smoking  eight  
hours  prior  to  scanning,  from  drinking  coffee  or  tea  12  hours  prior  to  
scanning,  and  from  drinking  alcohol  48  hours  prior  to  scanning.  The  
subjects  were  allowed  to  eat  a  normal  breakfast  prior  to  the  PET  
scans.  A  standard  hospital  lunch  was  served  between  scans.  To  
minimize  the  possible  effects  of  arousal  on  tracer  binding(Li and van den 
Pol, 2008),  the  subjects  were  not  allowed  to  sleep  in  the  scanner  
during  [11C]carfentanil  imaging.  One  HC  was  not  available  for  
[11C]carfentanil  analysis  due  to  scanner  malfunction,  and  three  subjects  
(1  HC  and  2  PG)  were  not  available  for  [18F]fluorodopa  analysis.   
 
All  included  subjects  underwent  brain  MRI  with  a  PET-MRI  scanner  
Philips  Ingenuity  (Philips  Healthcare,  Cleveland,  Ohio,  USA).  Anatomical  
reference  images  were  acquired  using  both  a  34-channel  receiving  head  
coil  and  a  sagittal  3DT1-weighted  TFE  sense  pulse  sequence  (TR  8.1  
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ms,  TE  3.7  ms,  flip  angle  7  degrees,  matrix  256  x  256,  176  slices)  
with  an  isotropic  voxel. 
 
Radiochemistry  and  PET  scanning 
Radioligands  were  produced  according  to  EU  GMP  regulations  at  the  
Turku  PET  Centre,  as  previously  described.(Forsback et al, 2009; 
Hirvonen et al, 2009)  [18F]FDOPA  was  synthetized  via  electrophilic  
radiofluorination.  [11C]Carfentanil  was  synthesized  via  11C-methylation  of  
desmethyl  carfentanil  (sodium  salt)  with  [11C]methyl  triflate  prepared  from  
cyclotron-produced  [11C]methane.  Radiochemical  purity  exceeded  95%  in  
all  production  runs,  and  the  specific  activity  was  more  than  5  GBq/µmol  
for  [18F]FDOPA  and  590  GBq/µmol  (SD  290)  for  [11C]carfentanil  at  the  
time  of  injection. 
 
PET  scanning  for  each  participant  was  performed  during  the  same  day  
at  fixed  times  ([11C]carfentanil  scan  at  09:00–10:00  am,  [18F]fluorodopa  
scan  at  02:30–03:30  pm).  For  four  subjects  (one  PG,  one  BE  and  two  
HC),  the  PET  scans  were  performed  on  separate  days.  PET  scanning  
was  performed  with  a  dedicated  brain  3D  HRRT  (High  Resolution  
Research  Tool,  Siemens  Medical  Solutions,  Knoxville,  TN,  USA)  PET  
scanner  with  nearly  isotropic  2.5  mm  intrinsic  spatial  resolution.(de Jong 
et al, 2007)  The  camera  was  used  in  3D  mode  with  scatter  correction.  
The  total  scanning  time  was  51  minutes  with  [11C]carfentanil  and  90  
minutes  with  [18F]fluorodopa.  The  [11C]carfentanil  scans  consisted  of  13  
frames,  and  the  [18F]fluorodopa  scans  were  divided  into  22  frames.  The  
average  doses  were  492  (SD  33)  MBq  for  [11C]carfentanil  and  228  (SD  
8)  MBq  for  [18F]fluorodopa.  A  transmission  scan  was  performed  prior  to  
each  dynamic  scanning  for  attenuation  corrections  with  a  137Cs  rotating  
point  source.  An  individually  shaped  thermoplastic  mask  was  used  with  
each  subject  to  minimize  head  movement,  and  head  movements  were  
recorded  using  a  stereotaxic  infrared  camera  (Polaris  Vicra,  Northern  
Digital,  Waterloo,  Canada)  during  scanning.  Three  PG  patients  and  1  
BED  patient  had  a  Velcro  strap  instead  of  a  thermoplastic  mask  during  
[18F]fluorodopa  scanning. 
	 8	
 
Preprocessing  and  analysis 
Realignment  and  coregistration  steps  were  performed  with  SPM8  
software  running  on  MatLab  R2012a  (MathWorks,  Natick,  MA,  USA).  
First,  dynamic  PET  images  were  realigned  frame-to-frame  to  correct  
head  movement  during  the  scanning.  Individual  T1-weighted  MR  images  
were  coregistered  to  the  summed  image  of  the  realigned  frames  and  
resliced  to  1.5  x  1.5  x  1.5  mm  voxel  size.  There  were  three  subjects  
who  showed  >  2  mm  intra-frame  head  movement  in  more  than  one  
frame  during  scanning  according  to  infrared  camera  data.  For  these  
three  subjects  and  five  scans,  individual  reconstructions  were  made  to  
compensate  for  intraframe  motion.  An  in-house  method  corresponding  to  
that  described  by  Keller  and  colleagues(Keller et al, 2012)  was  employed  
in  motion  correction  (MC)  reconstruction.  Shortly,  PET  list  mode  data  
were  first  subframed  according  to  Vicra-based  external  motion  data  
using  a  maximum  amplitude  of  2.5  mm  as  a  threshold.  Second,  all  
subframes  were  reconstructed  without  attenuation  correction,  and  
registering  transformations  to  a  reference  frame  were  estimated  using  
Automated  Image  Registration  (AIR)  software(Woods et al, 1998);  third,  
inverse  transformations  were  employed  to  register  attenuation  correction  
to  each  subframe  and  final  reconstructions  were  made  with  all  
corrections.  Finally,  the  subframes  were  registered  and  combined  to  
form  the  desired  framing. 
 
Individual  parametric  images  were  normalized  to  Montreal  Neurological  
Institute  (MNI)  standard  space  and  smoothed  with  a  Gaussian  kernel  of  
8  mm  at  full  width  and  half  maximum  (FWHM).  Complementary  with  
voxel-by-voxel  analyses,  tracer  kinetics  were  quantified  from  the  
anatomical  regions  of  interest  (ROIs).  ROIs  were  determined  using  
FreeSurfer  software  (version  5.3.0,  http://surfer.nmr.mgh.harvard.edu/)  
using  T1-weighted  MR  images,  as  described  earlier.(Alakurtti et al, 2015; 
Desikan et al, 2006; Fischl et al, 2002)  ROIs  selected  for  [11C]carfentanil  
analyses  included  the  putamen,  nucleus  caudatus,  nucleus  accumbens,  
globus  pallidus,  thalamus,  hippocampus,  amygdala  and  cortical  gray  
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matter  areas  (for  a  complete  list,  see  Supplementary  Table  S1),  
whereas  the  ROIs  included  in  [18F]fluorodopa  consisted  only  of  the  
subcortical  regions  putamen,  nucleus  caudatus,  nucleus  accumbens,  
globus  pallidus,  thalamus,  hippocampus  and  amygdala.  [11C]carfentanil  
binding  potentials  (estimates  of  specific  binding  relative  to  non-
displaceable  binding  or  BPND)  were  calculated  using  a  simplified  
reference  tissue  model  and  [18F]fluorodopa  influx  rate  constant  Ki  values  
using  a  Patlak  plot,  both  with  the  occipital  cortex  as  a  reference  
region.(Gunn et al, 1997; Patlak and Blasberg, 1985) 
 
Statistics 
Statistical  analyses  were  performed  using  SPSS  (IBM  SPSS  Statistics,  
version  22,  Armonk,  NY,  USA).  Group  differences  in  demographic  data,  
questionnaire  data  and  ROI  data  were  investigated  using  an  ANOVA  
model  (three  groups)  or  Chi-Square  tests  for  categorical  variables.  
Within-group  correlations  between  tracer  kinetics  and  
demographical/questionnaire  data  were  tested  using  Spearman’s  rank  
order  test.  In  the  ROI  analysis,  p  <  0.01  was  considered  statistically  
significant  to  take  into  account  the  effect  of  multiple  comparisons.  
Analogous  voxel-based  analyses  were  performed  using  a  general  linear  
model  implemented  in  SPM8.  In  SPM,  cluster-level  family-wise  error  
(FWE)  corrected  P-values  less  than  0.05  were  considered  significant.   
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Results 
Patients  with  BED  had  lower  [11C]carfentanil  BPND  than  healthy  controls  
and  PG  patients  in  several  brain  regions,  including  the  thalamus,  the  
nucleus  accumbens,  the  hippocampus,  the  posterior  cingulate  gyrus,  the  
isthmus  of  the  posterior  cingulate  gyrus,  the  parahippocampal  gyrus,  the  
frontal  pole,  the  pars  orbitalis  of  the  ventrolateral  prefrontal  cortex,  the  
lateral  orbitofrontal  cortex  and  the  ventrolateral  prefrontal  cortex  (Table  
3,  Figure  1,  Table  S1)  in  the  ROI-based  analysis.  The  largest  
decreases  in  BED  compared  with  PG  patients  were  observed  in  the  
hippocampus  (66%  lower  in  BED,  p  =  0.010),  the  frontal  pole  (56%  
lower  in  BED,  p  <  0.0001)  and  the  isthmus  of  the  posterior  cingulate  
gyrus  (54%  lower  in  BED,  p  <  0.0001).  In  the  nucleus  accumbens,  
BED  patients  had  30%  lower  [11C]carfentanil  binding  than  PG  patients  
(p  <  0.0001)  (Table  3).  With  [18F]fluorodopa,  patients  with  BED  had  
lower  Ki  than  healthy  controls  and  PG  patients  in  the  nucleus  
accumbens  (20%  with  p  <  0.001  and  20%  with  p  =  0.001,  respectively)  
(Table  3,  Figure  1,  Table  S1).  All  other  group  comparisons  were  non-
significant.   
 
The  results  remained  the  same  when  males  (Figure  1C  and  1D)  and  
smokers  (Figure  1E  and  1F)  were  excluded  from  the  analysis.  
Furthermore,  including  BMI,  age  or  AUDIT  score  as  covariates  in  
ANOVA  did  not  change  the  primary  results.   
 
Correlation  analyses  with  ROI  values  were  performed  with  
[18F]fluorodopa  Ki  for  the  nucleus  accumbens  and  [11C]carfentanil  BPND  
for  the  regions  that  showed  the  largest  group  differences  (the  isthmus  
of  the  cingulate,  the  nucleus  accumbens,  the  frontal  pole  and  the  pars  
orbitalis  of  the  ventrolateral  prefrontal  cortex).  In  BED  patients,  no  
significant  correlations  were  observed  with  symptom  severity  scores  
including  the  DEBQ,  BES  and  Yale  food  addiction  scale  score.  In  PG  
patients,  tracer  binding  did  not  correlate  with  gambling-related  severity  
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ratings  such  as  gambling  hours  per  week  or  SOGS.  Correlations  were  
similarly  non-significant  using  both  ROI-  and  SPM-based  analyses.   
 
An  independent  voxel-based  whole-brain  analysis  using  SPM  confirmed  
the  ROI-based  results  by  showing  a  large  cluster  of  lower  
[11C]carfentanil  binding  in  BED  patients  compared  with  controls,  
particularly  in  the  posterior  cingulate  gyrus,  the  thalamus,  the  anterior  
cingulate  gyrus  and  the  midbrain  (Figure  2A).  Differences  in  
[11C]carfentanil  BPND  were  also  observed  between  BED  and  PG  in  the  
frontal  cortex  (lower  in  BED,  cluster  size  59.9  cm3,  peak  voxel  at  -9,  
63,  33  mm,  tmax=6.18,  pFWE  <  0.001)  and  between  PG  patients  and  
controls  bilaterally  in  the  anterior  cingulate  cortex  and  posterior  cingulate  
cortex  (lower  in  PG,  Figure  2A).  With  [18F]fluorodopa,  SPM  analysis  
confirmed  a  lower  uptake  in  BED  compared  with  controls  in  the  
nucleus  accumbens  with  the  cluster  extending  to  the  caudate  and  
putamen  (Figure  2B).  No  significant  Ki  differences  were  detected  with  
SPM  in  the  comparisons  between  the  PG  and  controls  or  between  PG  
and  BED.   
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Discussion 
We  show  that  two  phenotypically  different  behavioral  patterns,  PG  and  
BED,  are  dissociable  as  a  function  of  brain  opioid  and  dopamine  
neurotransmission.  BED  is  characterized  by  a  widespread  reduction  in  
mu-opioid  receptor  availability  and  striatal  dopamine  synthesis  capacity,  
whereas  PG  was  only  associated  with  a  reduction  in  mu-opioid  receptor  
availability  in  the  cingulate  cortex.  These  findings  have  important  
implications  in  the  conceptualization  of  disorders  of  addiction  and  in  
possible  mechanistic  and  therapeutic  efficacy. 
 
Mu-Opioid  receptor 
Contrary  to  our  hypotheses,  the  reduced  mu-opioid  receptor  availability,  
particularly  in  BED  and  to  a  lesser  extent  in  PG,  stand  in  marked  
contrast  to  observations  in  substance  use  disorders.  Elevated  mu-opioid  
receptor  availability  is  observed  in  cocaine(Zubieta et al, 1996)  and  
alcohol(Heinz et al, 2005)  dependence  in  early  abstinence  and  is  
associated  with  craving,  severity  and  predicted  relapse  and  remains  
stable  in  early  to  mid-abstinence.  These  findings  may  reflect  either  
differences  in  the  regulation  of  the  mu-opioid  receptor  or  endogenous  
opioid  release  as  a  function  of  drugs  or  exposure  to  natural  rewards  or  
pathological  behaviors;  alternatively,  they  may  reflect  predisposing  traits.   
 
Morbid  obesity  has  been  associated  with  low  mu-opioid  receptor  
availability,  and  bariatric  surgery  appears  to  normalize  low  mu-opioid  
receptor  availability  despite  the  patients  being  overweight  after  
surgery.(Karlsson et al, 2015)  This  particular  study  suggests  that  an  
alteration  in  opioid  function  may  be  more  likely  to  be  associated  with  
pathological  eating  behavior  than  with  body  mass.  Here,  we  focus  on  
pathological  binge  eating  behaviors  in  subjects  with,  on  average,  slightly  
to  moderately  elevated  BMI  (mean  30.9  (SD  6.6)  kg/m2;  range  22.8  –  
42.1)  and  show  that  BMI  does  not  influence  [11C]carfentanil  binding.  
Further  studies  are  required  to  explore  the  relationship  between  mu-
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opioid  receptor  availability  and  chronic  over-eating  compared  with  binge  
eating  specifically. 
 
Our  findings  are  consistent  with  a  recent  study  in  PG  demonstrating  a  
blunting  of  amphetamine-induced  changes  in  mu-opioid  receptor  
availability  but  without  any  differences  in  baseline  receptor  
availability.(Mick et al, 2015)  The  present  voxel-based  results  suggest  
reductions  in  mu-opioid  receptor  availability  in  the  cingulate  cortex  in  
PG;  however,  this  finding  was  not  confirmed  in  our  ROI  analysis,  which  
utilized  predefined  anatomical  ROIs.  The  finding  of  decreased  cingulate  
mu-opioid  receptor  availability  should  therefore  be  considered  preliminary  
and  warrants  replication.  In  addition,  [11C]carfentanil  BPND  values  of  our  
healthy  controls  were  somewhat  lower  compared  to  some  earlier  PET  
studies  (Mick  et  al,  2015,  Karlsson  et  al,  2015,  Hirvonen  et  al,  2009).  
The  difference  in  BP  ND  levels  are  probably  caused  by  differences  in  
methodology  (scanner,  software,  ROIs)  and/or  subject  characteristics  
between  the  studies.  However,  possible  methodological  differences  
compared  to  the  earlier  studies  have  no  effect  on  the  robust  group  
differences  presented  here. 
 
These  findings  have  implications  for  possible  cognitive  mechanisms  and  
the  therapeutic  efficacy  of  mu-opioid  antagonists.  Abnormalities  were  
observed  predominantly  in  key  structures  related  to  reward  processing,  
such  as  the  nucleus  accumbens,  lateral  orbitofrontal  cortex,  ventrolateral  
prefrontal  cortex,  hippocampus  and  thalamus  with  [11C]carfentanil.(Haber 
and Knutson, 2010)  The findings may reflect either lower mu-opioid receptor 
density or greater endogenous opioid release. The  mu-opioid  receptor  is  
implicated  in  hedonic  processing(Berridge et al, 2009)  and  incentive  
motivation(Cambridge et al, 2013; Ziauddeen et al, 2013).  In  humans  with  
moderate  binge  eating,  mu-opioid  receptor  antagonism  appears  to  
decrease  motivational  responses  to  salient  food  cues  and  enhance  
subjective  hedonic  ratings  to  food  cues  for  which  effort  or  motivation  
was  expended  but  decrease  hedonic  ratings  to  sweetened  food  
consumption(Cambridge et al, 2013; Voon, 2015; Ziauddeen et al, 2013).  
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Thus,  low  baseline  mu-opioid  receptor  availability  may  increase  pleasure  
associated  with  food  cues  or  the  expectation  of  food  for  which  effort  is  
expended  but  decrease  pleasure  associated  with  the  act  of  consumption,  
thereby  leading  to  out-of-control  binge  eating  behaviors.  Two  novel  
compounds  targeting  the  mu-opioid  receptor  have  not  shown  efficacy  in  
binge  eating  or  weight  control (McElroy et al, 2013)-(Ziauddeen et al, 2013).  
This  lack  of  efficacy  of  mu-opioid  receptor  antagonists  in  BED  contrasts  
with  their  efficacy  in  substance  use  disorders  and  particularly  alcohol  
use  disorders(Rosner et al, 2010),  an  observation  that  may  reflect  the  
differences  in  baseline  receptor  availability.  Further studies investigating 
mu-opioid receptor availability as a marker for treatment response is indicated.   
 
We  note  that  midbrain  [11C]carfentanil  binding  was  decreased  in  BED  
patients  compared  to  PG  patients  and  controls,  without  similar  
differences  in  [18F]fluorodopa  binding.  This  suggests  that  the  reduced  
mu-opioid  receptor  availability  may  be  an  independent  finding  even  in  
dopamine-rich  areas,  despite  the  crosstalk  between  mu-opioid  receptors  
and  dopamine  neurons.(Li et al, 2016) 
 
Dopamine  synthesis  capacity 
We  further  highlight  differences  in  BED  and  PG  as  a  function  of  striatal  
dopamine  synthesis  capacity  with  decreased  capacity  in  BED  with  no  
differences  observed  in  PG.  These  findings  corroborate  observations  of  
mixed  findings  across  substance  use  disorders.  Cocaine  use  disorders  
are  associated  with  lower  dopamine  synthesis  capacity(Wu et al, 1997)  
with  no  differences  observed  for  alcohol(Kienast et al, 2013)  or  nicotine  
use  disorders(Bloomfield et al, 2014).  The  observation  of  low  striatal  
dopamine  synthesis  capacity  in  BED  may  be  particularly  relevant  to  the  
efficacy  of  lisdexamfetamine  in  BED(McElroy et al, 2015),  which  inhibits  
dopamine  and  noradrenergic  transporters  and  enhances  synaptic  
neurotransmitter  levels.  Our  findings  may  be  relevant  as  potential  
biomarkers  for  the  therapeutic  efficacy  for  lisdexamfetamine. 
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We  previously  showed  that  PG  is  not  associated  with  differences  in  D2  
receptor  availability  relative  to  controls(Joutsa et al, 2012),  which  has  
been  confirmed  by  other  studies.(Boileau et al, 2013; Clark et al, 2012)  
Together  with  our  current  study,  these  observations  suggest  that  there  
is  no  marked  group-level  basal  pre-  or  postsynaptic  dopaminergic  hypo-  
or  hyperactivity  in  PG.  Although  dopamine  agonists  can  induce  
pathological  gambling(Weintraub et al, 2010),  dopamine  D2  receptor  
availability  and  dopamine  synthesis  capacity  are  unaltered  in  PG  
patients  (in  contrast  with  observations  in  substance  addictions).  Our  
findings  are  consistent  with  recent  theories  that  subtypes  of  addictions,  
namely  opiate  and  psychostimulant  use  disorders,  are  behaviorally  and  
neurobiologically  distinct.(Badiani et al, 2011)  These  results  extend  this  
concept  of  heterogeneity  to  behavioral  addictions.   
 
Limitations 
Although  we  note  that  our  sample  size  of  BED  subjects  was  relatively  
small  due  to  difficulties  in  recruiting  suitable  subjects,  and  thus  these  
results  need  replication  in  future  studies,  we  compared  this  with  a  large  
healthy  control  population  (total  sample  of  BED  and  healthy  controls:  
24).  Furthermore,  we  emphasize  that  the  effect  size  for  the  difference  
between  BED  and  healthy  controls  in  the  nucleus  accumbens  was  large  
for  both  neurotransmitter  effects  (e.g.,  nucleus  accumbens  
[11C]carfentanil  Cohen’s  d:  2.77,  effect  size  r=0.81;  [18F]fluorodopa  
Cohen’s  d:  2.37,  effect  size  r=0.76).  We  also  accounted  for  possible  
effects  that  may  act  as  confounders  (e.g.,  addiction  severity,  medication,  
gender,  concurrent  smoking  and  depression)  and  suggest  that  these  
factors  are  unlikely  to  explain  our  findings.  Both  PG  and  BED  fulfilled  
diagnostic  criteria  with  daily  urges  to  gamble  or  binge  eat;  notably,  
BED  subjects  had  a  longer  duration  of  disease  relative  to  PG  subjects.  
However,  neither  symptom  severity  nor  duration  correlated  with  binding.  
Similar  to  the  gender  distribution  of  BED  and  PG  in  the  general  
population(Kessler et al, 2013; Kessler et al, 2008),  our  sample  had  more  
PG  males  and  only  females  with  BED.  However,  a  specific  analysis  of  
female  subjects  did  not  affect  the  results.  Because  smoking  is  also  a  
	 16	
potential  confounding  factor,  the  results  were  confirmed  in  non-smoking  
subjects  only.  The  depression  scores  were  also  comparable  between  
BED  and  PG,  and  major  depression  was  an  exclusion  criterion,  which  
suggested  that  depression  was  unlikely  to  account  for  these  findings.  
Finally,  participants  were  not  using  medications  known  to  have  effects  
on  opioid  or  dopamine  system. 
 
Conclusion 
In  summary,  we  emphasize  intrinsic  differences  in  opioid  and  dopamine  
function  between  two  subtypes  of  behavioral  addictions.  These  findings  
highlight  the  heterogeneity  of  subtypes  of  addictions  and  may  also  
reflect  potential  neurobiological  substrates,  which  could  lead  an  
individual  towards  the  pathological  use  of  a  specific  drug  or  behavior.  
Our  findings  also  have  implications  for  underlying  cognitive  and  
therapeutic  mechanisms  and  could  potentially  be  used  as  biomarkers  for  
treatment. 
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Figure  legends 
 
Figure  1.  Nucleus  accumbens  [11C]carfentanil  binding  potentials  (BPND)  
and  [18F]fluorodopa  Ki  values  in  healthy  controls  (C),  pathological  
gamblers  (PG)  and  binge  eaters  (BE).  Statistical  significance  denotes  
Bonferroni-corrected  post-hoc  tests  after  one-way  ANOVA.  ***p<0.001,  
**p<0.01,  *p<0.05,  NS  =  non-significant.  Means  of  the  left  and  right  
hemisphere  values  are  presented.  A.  [11C]carfentanil,  all  subjects.  B.  
[18F]fluorodopa,  all  subjects.  C.  [11C]carfentanil,  women  only.  D.  
[18F]fluorodopa,  women  only.  E.  [11C]carfentanil,  non-smokers  only.  F.  
[18F]fluorodopa,  non-smokers  only. 
 
Figure  2.  Between-group  differences  in  [11C]carfentanil  binding  potentials  
(BPND)  and  [18F]fluorodopa  Ki  values.  Significant  clusters  from  the  level  
of  the  nucleus  accumbens  are  shown  on  the  left.  On  the  right  are  
significant  clusters  from  the  level  of  the  left  cingulate  cortex.  The  
yellow-colored  clusters  illustrate  the  areas  where  BED  patients  had  
lower  tracer  binding  compared  with  controls,  whereas  the  green-colored  
clusters  show  the  areas  where  tracer  binding  was  lower  within  PG  
patients  compared  with  controls.  A.  [11C]carfentanil:  BED  (cluster  size  
248.8  cm3,  peak  voxel  at  -66,  -51,  -6  mm,  tmax=6.15,  pFWE  <  0.001)  PG  
(cluster  size  45.6  cm3,  peak  voxel  at  20  -24  34  mm,  tmax=6.04,  
pFWE=0.001).  B.  [18F]fluorodopa:  BED  (cluster  size  16.5  cm3,  peak  voxel  
at  -6,  11,  -12  mm,  tmax  =  5.16,  pFWE  <  0.001).   
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Table 1. Main demographic characteristics of the studied sample. Values are 
means (SD) or n. 
 
 
HC PG BED P-
value1 
n 17 15 7  
Age (years) 43.3 
(11.1) 
42.6 
(11.8) 
49.4 (5.1) 0.35 
Sex (m/f) 8/9 8/7 0/7 0.048 
BMI (kg/m2) 24.8 (2.1) 25.4 (3.6) 30.9 (6.6) 0.003 
Smoking (y/n) 7/10 11/4 2/5 0.08 
BDI 2.8 (3.1) 14.4 (7.8) 15.4 (9.6) <0.0001 
Injected dose of 
[11C]carfentanil  (MBq) 
495 (17) 483 (49) 504 (13) 0.35 
Injected mass of 
[11C]carfentanil  (µg) 
0.428 
(0.307) 
0.569 
(0.542) 
0.422 
(0.197) 
0.56 
Injected dose of 
[18F]fluorodopa   (MBq) 
228 (4) 229 (12) 225 (6) 0.67 
Injected mass of 
[18F]fluorodopa   (µg) 
9.30 
(3.31) 
11.28 
(3.59) 
10.54 
(5.88) 
0.40 
AUDIT 5.4 (3.3) 5.9 (4.0) 3.3 (1.1) 0.23 
 
1One-way ANOVA or Chi-Square test 
BMI= body mass index, BDI= Beck Depression Inventory, AUDIT= Alcohol 
Use Disorders Identification Test 	
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Table 2.  Differences between studied groups in gambling and eating.  
Behavior Item Control PG BED P-value1 
n 17 15 7 
 
 
 
Gambling 
PG DSM-IV 0.1 (0.3) 7.3 (1.4) 0 (0) <0.0001 
SOGS 0.1 (0.3) 13.3 (2.3) 0.4 (0.5) <0.0001 
Duration of problem gambling 
(years) 
0 (0) 11.6 (7.3) 0 (0) <0.0001 
Gambling per week (€) 3.9 (7.4) 152 (149) 2.9 (4.6) <0.0001 
Gambling per week (hours) 0.5 (1.2) 8.7 (7.2) 0.5 (1.2) <0.0001 
Gambling debt (€) 0 (0) 18000 (15600) 0 (0) <0.0001 
 
 
Eating 
 
 
Binge Eating Scale 2.1 (2.1) 4.4 (4.4) 30.9 (4.6) <0.0001 
Yale food addiction scale 5.4 (3.4) 9.1 (9.5) 42.3 (6.5) <0.0001 
DEBQ emotional 20.5 (5.0) 21.2 (8.7) 50.0 (8.3) <0.0001 
DEBQ external 23.7 (5.3) 26.1 (7.3) 37.5 (6.3) <0.0001 
DEBQ restrained 24.8 (6.8) 20.9 (10.6) 35.3 (3.4) 0.002 
Duration of problem eating (yrs) 0 (0) 0 (0) 18.1 (14.9) <0.001 
1One-way ANOVA 
Missing questionnaire data for one PG patient. 
PG DSM-IV = DSM-IV diagnostic criteria for pathological gambling, SOGS = South Oaks Gambling Screen, DEBQ = The Dutch Eating Behavior 
Questionnaire 
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Table 3. Group-differences in [11C]carfentanil BPND and [18F]fluorodopa Ki values (ROI-analysis). Regions with a significance level of P<0.01 in 
ANOVA are presented. Other regions-of-interest are presented in Supplementary Table S1.  
Tracer Region HC PG BED F-value 
 
One-way 
ANOVA 
P-value 
 
One-way 
ANOVA 
               P-value  
     Post hoc Bonferroni 
 
C vs PG 
 
C vs 
BED 
 
PG vs BED 
 
 
 
 
 
[11C]carfentanil  
Isthmus of PCC 0.469 
(0.092) 
0.416 (0.113) 0.191 (0.089) 18.9 <0.0001 0.468 <0.0001 <0.0001 
Nucleus accumbens  2.27 (0.26) 2.12 (0.33) 1.49 (0.29) 17.5 <0.0001 0.502 <0.0001 <0.0001 
Frontal pole  0.765 
(0.206) 
0.803 (0.244) 0.350 (0.177) 11.4 <0.0001 1.000 0.001 <0.0001 
Pars orbitalis of VPC 0.809 
(0.152) 
0.777 (0.181) 0.495 (0.087) 10.6 <0.0001 1.000 <0.0001 0.001 
Parahippocampal 
gyrus 
0.296 
(0.086) 
0.259 (0.086) 0.142 (0.100) 7.5 0.002 0.755 0.001 0.019 
PCC 0.874 
(0.166) 
0.856 (0.144) 0.630 (0.159) 6.5 0.004 1.000 0.005 0.010 
Thalamus  1.41 (0.18) 1.33 (0.25) 1.07 (0.17) 6.5 0.004 0.981 0.003 0.027 
Hippocampus 0.211 
(0.089) 
0.218 (0.107) 0.0736 
(0.108) 
5.7 0.007 1.000 0.013 0.010 
LOF 0.868 
(0.126) 
0.853 (0.181) 0.650 (0.119) 5.7 0.007 1.000 0.008 0.016 
VPC 0.830 
(0.142) 
0.797 (0.182) 0.605 (0.092) 5.5 0.008 1.000 0.008 0.028 
 
[18F]fluorodopa   
 
Nucleus accumbens 0.0115 
(0.0011) 
0.0114 
(0.0014) 
0.00915 
(0.00104) 
10.4 <0.0001 1.000 <0.0001 0.001 
 
PCC = posterior cingulate gyrus, VPC = ventrolateral prefrontal cortex, LOF = lateral orbitofrontal cortex 
VPC is formed by fusing primary ROIs pars opercularis, pars orbitalis and pars triangularis. 	


